Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | prolyl oligopeptidase family protein | 0.0146 | 0.6507 | 0.632 |
Leishmania major | prolyl oligopeptidase, putative,serine peptidase clan SC, family S9A, putative | 0.0146 | 0.6507 | 1 |
Trypanosoma brucei | Dipeptidyl-peptidase 8-like, putative | 0.0073 | 0.051 | 0.0784 |
Leishmania major | dipeptidyl-peptidase 8-like serine peptidase, putative,serine peptidase, Clan SC, Family S9B | 0.0073 | 0.051 | 0.0784 |
Echinococcus multilocularis | dipeptidyl aminopeptidaseprotein | 0.0189 | 1 | 1 |
Schistosoma mansoni | prolyl oligopeptidase (S09 family) | 0.0146 | 0.6507 | 0.632 |
Echinococcus granulosus | dipeptidyl aminopeptidaseprotein | 0.0189 | 1 | 1 |
Mycobacterium ulcerans | protease II (oligopeptidase B), PtrB | 0.0067 | 0 | 0.5 |
Mycobacterium leprae | PROBABLE PROTEASE II PTRBB (OLIGOPEPTIDASE B) | 0.0067 | 0 | 0.5 |
Onchocerca volvulus | Dipeptidyl peptidase family member 1 homolog | 0.0189 | 1 | 1 |
Trypanosoma cruzi | prolyl endopeptidase | 0.0146 | 0.6507 | 1 |
Echinococcus multilocularis | prolyl endopeptidase | 0.0146 | 0.6507 | 0.632 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S9B | 0.0073 | 0.051 | 0.0784 |
Schistosoma mansoni | subfamily S9B unassigned peptidase (S09 family) | 0.0189 | 1 | 1 |
Echinococcus granulosus | prolyl endopeptidase | 0.0146 | 0.6507 | 0.632 |
Loa Loa (eye worm) | prolyl oligopeptidase | 0.0189 | 1 | 1 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S9B | 0.0073 | 0.051 | 0.0784 |
Trypanosoma cruzi | dipeptidyl-peptidase 8-like serine peptidase | 0.0073 | 0.051 | 0.0784 |
Toxoplasma gondii | prolyl endopeptidase | 0.0146 | 0.6507 | 1 |
Trypanosoma brucei | prolyl endopeptidase | 0.0146 | 0.6507 | 1 |
Mycobacterium tuberculosis | Probable protease II PtrBa [first part] (oligopeptidase B) | 0.0119 | 0.4241 | 1 |
Schistosoma mansoni | prolyl oligopeptidase (S09 family) | 0.0146 | 0.6507 | 0.632 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.